Keyword: Kyprolis


12. Amgen

It was a transitional year for Amgen: Demand for newer products Kyprolis, Prolia and Repatha just wasn’t enough to offset declines in some mature brands, including Enbrel, Neulasta and Epogen.

7. Darzalex

When Johnson & Johnson launched its multiple myeloma drug Darzalex in 2015, it knew it had its work cut out to carve out market share. Its drug was reserved for fourth-line use, setting it behind closest competitors Pomalyst from Celgene and Amgen's Kyprolis in the treatment sequence.